Table 2.

Clinical and Drug Resistance Data from Women Exposed to sdNVP and Starting on NVP-Containing ART^a

Patient	Time after sdNVP prior to HAART (months)	Time to failure/follow-up (months)	Viral load (log10)	CD4 count (cells/μl)	%103K (AAA) (AAG)	%103N (AAC)	%103N (AAT)	%181Y (TAT)	%181C (TGT)	Viroseq results at failure
1b,c	10	6	5.88	54	100	—	—	99.76	0.20	184V/190A
2b,c	5.25	6	4.45	46	97.99	1.95	—	99.88	0.10	103N
3b	9.5	5.5	5.88	48	100	—	—	98.1	0.35	181C/184V
4b	5.5	5.5	5.88	22	95.17	3.14	1.69	99.85	0.13	103N/181C/184V
5b	3.25	6.75	4.79	n/a	98.96	0.84	0.20	99.9	—	—
6b	6	7.5	5.27	84	99.98	—	—	99.75	0.24	103N
7b,c	1	5	5.31	151	99.98	—	—	99.6	0.10	103N
8c	14.75	24	3.78	179	99.94	—	—	99.56	0.14
9	12.25	25	5.88	292	98.65	1.34	—	99.87	0.12
10	19	22.75	5.88	n/a	99.54	0.45	—	99.56	0.44
11	13.75	25	4.80	171	100	—	—	99.62	0.35
12	8.5	24.5	5.02	226	99.99	—	—	99.9	—
13	0	31	2.94	261	99.84	—	—	99.91	—
14	1	30	5.47	117	93.56	2.44	4.11	99.69	0.29
15	9.5	17.5	4.51	n/ad	99.98	—	—	99.85	0.13
16	1	24	4.75	156	100	—	—	99.79	—
17	7.25	55.75	5.44	50	99.98	—	—	99.96	—
18	13	47	4.74	206	99.98	—	—	99.96	—
19	16.5	41.5	5.88	246	99.97	—	—	99.8	0.17
20c	38.5	17.5	4.90	132	96.89	3.11	—	99.96	—
21	7	54	5.72	155	99.99	—	—	99.9	—
22	12	41	3.73	294	99.99	—	—	99.98	—
23	12	37	3.48	200	99.97	—	—	99.92	—
24	9.5	41.75	5.02	174	96.5	3.5	—	99.95	—
25	7	45	5.26	171	99.99	—	—	99.94	—
26	1.5	43	4.86	179	99.88	0.13	—	99.95	—

^aPatients 1–7 were those who experienced virologic failure after starting NVP-containing ART after exposure to sdNVP. Cells with dash marks represent negative results (either no mutations are present when the cloning sequence was performed or the result is below the clinical cutoff on the ASPCR assay).

^bVirologic failure following treatment with NVP-containing ART.

^cPatient with detectable resistance by cloning and sequencing.

^d—, data not available.